The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor ... meningococcal infections caused by Neisseria meningitidis that is on Soliris ...

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have ...

The shot protects against common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y), covering five of the six serogroups that cause most disease worldwide, with the B ...